EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Sensus Healthcare Inc (SRTS) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Sensus Healthcare Inc $1.78, price $3.03, upside -41.3%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US81728J1097

SH Sensus Healthcare Inc logo Thin data Sep 23, 2026

Sensus Healthcare Inc

SRTS · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $1.78 · Strongly overvalued (−41%)
!Quality 50/100
!Weak Growth (revenue 3y −14.9 %/yr)
!Loss-making · -34.5% net margin (TTM)
✓Low debt · generates free cash flow
!Trails peers (4/11)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
Watch Sensus Healthcare Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$14.97 $1.87 Fair Value $1.78 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $1.87 – $14.97 · fair‑value band $1.56 – $2.06 · the $3.03 price screens above the $1.78 fair value. Dashed = 300-day average. As of Sep 23, 2026.

Follow Sensus Healthcare in your weekly email

Every Wednesday you see whether Sensus Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices.

Show more

Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 +; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos, as well as provide operational healthcare services for dermatology clinics. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. The company was incorporated in 2010 and is based in Boca Raton, Florida.

Stock analysis

Sensus Healthcare Inc (SRTS) currently trades at $3.03, while our model-based Fair Value estimate is $1.78, implying the stock looks roughly 70.2% overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of $1.96 per share, and 0 of the 7 models we run sit above the $3.03 price.

Bear case: the Multiples group reads lowest at $1.59, and 7 of the 7 models stay below the price. Evidence for this calculation is low.

Scenario range: $1.56 (bear) to $2.06 (bull), the price of $3.03 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Sensus Healthcare Inc reported revenue of $27.5M in FY2025 versus $27.0M in FY2021, a compound +0.4%/yr. Reported net income was −$7.7M in FY2025.

Key figures

Market cap $49.5M · P/S ratio 1.99 · EPS (TTM) $−0.4700 · Net margin −28.1% · Return on equity −15.8% · Return on assets (EBIT) 6.4% · Operating margin −128% · Revenue (TTM) $22.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 43% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −41%, SRTS screens richer than that median.

Fair Value models

Bear $1.56 Fair Value $1.78 Bull $2.06
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $1.63 $1.82 $2.36 82
Growth DCF $1.61 $1.87 $2.34 80
5Y Revenue Exit $1.55 $1.73 $2.07 74
All 7 models by family
DCF Models
FCF DCF $1.63 $1.82 $2.36 82
5Y Revenue Exit $1.55 $1.73 $2.07 74
10Y Revenue Exit $1.56 $1.79 $2.05 68
Multiples
EV/Revenue $1.51 $1.59 $1.67 54
Asset-Based
NCAV (Graham) $1.46 $1.96 $2.92 54
Growth DCF
Growth DCF $1.61 $1.87 $2.34 80
Rev-Margin DCF $1.55 $1.75 $2.06 74

Open the full fair value analysis →

Notify me when SRTS reaches fair value

Put SRTS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 50/100

Of which business quality 52 · Market factors (momentum, volatility) 29

Profitability 15
Margins and returns on capital today
Quality Growth 0
Are margins and returns improving?
Cashflow 29
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 27
Calm price path (market factor)
Momentum 34
Price trend over the last 3–12 months (market factor)
52W Momentum 21
Distance to the 52-week high (market factor)
Net Issuance 86
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 10/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−34.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.9%
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−86.0% (2020) → −37.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+38.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+24.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +34.8% a year for the price and +21.1% for the forecasts.
Forecast 2026 (sales)−15.7%
Forecast 2027 (sales)+44.7%
Projected 2028 (sales)+39.3%
Projected 2029 (sales)+34.0%
Projected 2030 (sales)+28.7%

SRTS screens 70% overvalued. Compare with Abbott Laboratories, →

Earlier news

News mood ⓘNews mood, the average tone of recent news (94 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare Sensus Healthcare Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 50 · Above median
Fair Value upside −41% · Below median
Profitability
Return on assets −13% · Bottom 25%
Net margin (TTM) −35% · Bottom 25%
Operating margin (TTM) −128% · Bottom 25%
Growth and dividend
Revenue growth −59% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 1.03× · Cheaper than median
P/S (TTM) 2.20× · Cheaper than median
P/FCF 149.0× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 10
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 7
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 40

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $103.49 $74.79 −28%
Stryker Corporation SYK $273.40 $300.74 +10%
Medtronic plc MDT $89.30 $65.57 −27%
Boston Scientific Corporation BSX $44.62 $49.08 +10%
Edwards Lifesciences Corporation EW $86.82 $82.04 −6%
Siemens Healthineers AG SHL €37.21 €35.22 −5%
DexCom, Inc DXCM $87.73 $96.50 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sensus Healthcare Inc · Fair Value
$1.78 −70%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Sensus Healthcare Inc Fair Value". https://www.fairvalue-calculator.com/stock/SRTS

Frequently asked questions

Is Sensus Healthcare Inc (SRTS) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $1.78 versus a price of $3.03, about −41% upside (overvalued).
What is the fair value of SRTS?
Our model-based fair value for Sensus Healthcare Inc is $1.78 (as of Sep 23, 2026), built from audited fundamentals. The current price: $3.03.
What is the quality score of SRTS?
Sensus Healthcare Inc has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sensus Healthcare Inc (SRTS)?
Our model-based price target is the fair value of $1.78 (as of Sep 23, 2026) from 7 valuation models. Cautious scenario $1.56, optimistic scenario $2.06. It is a calculation from audited fundamentals, not an analyst target.
What is the Sensus Healthcare Inc stock forecast for 2026?
Our models put fair value at $1.78, about −41% upside versus a price of $3.03 (overvalued). Cautious scenario $1.56, optimistic scenario $2.06. The calculation is refreshed regularly with new filings.
What is the revenue of Sensus Healthcare Inc (SRTS)?
Sensus Healthcare Inc reported trailing-twelve-month revenue of about $22.5M (latest available figure, as of Sep 23, 2026).
What growth is priced into Sensus Healthcare Inc (SRTS)?
For today's price to be fair in a discounted-cash-flow model, Sensus Healthcare Inc would have to grow free cash flow by +38.0 % per year for five years (discount rate 10.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +23.5 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of SRTS use?
Our models discount Sensus Healthcare Inc at 10.0 %: a base by market capitalisation (nano), damped by beta 1.09, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sensus Healthcare Inc that is +38.0 % per year a year over ten years, using the same discount rate (10.0 %) and the same formula as our fair value.
How much growth has Sensus Healthcare Inc (SRTS) delivered so far?
Over the past 5 years revenue at Sensus Healthcare Inc grew +23.5 % a year. The price currently implies +38.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sensus Healthcare Inc (SRTS) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Sensus Healthcare Inc (+38.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sensus Healthcare Inc (SRTS)?
The free-cash-flow yield on the price is 0.67 %: that much free cash flow Sensus Healthcare Inc produces per unit of market value. When it exceeds the discount rate of our models (10.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sensus Healthcare Inc (SRTS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sensus Healthcare Inc it is $1.78 per share (as of Sep 23, 2026), against a price of $3.03. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Sensus Healthcare Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, SRTS trades above its calculated fair value: price $3.03, fair value $1.78, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SRTS?
No. The price is what the market pays today ($3.03); the fair value is what the company's own numbers justify ($1.78). For Sensus Healthcare Inc the two are $1.25 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sensus Healthcare Inc worth?
The market values Sensus Healthcare Inc at about $49.5M (market capitalisation, as of Sep 23, 2026). Per share that is $3.03; our models calculate a fair value of $1.78 per share.
What do the bullish and bearish scenarios say about SRTS?
Our models span a range for Sensus Healthcare Inc: cautious scenario $1.56, base $1.78, optimistic $2.06 per share (as of Sep 23, 2026, price $3.03). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sensus Healthcare Inc (SRTS)?
Balance-sheet figures for Sensus Healthcare Inc (as of Sep 23, 2026): return on equity −15.8%, debt of 0.01 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is SRTS from its 52-week high?
Sensus Healthcare Inc trades at $3.03, about 43% below its 52-week high of $5.30 and 13% above the low of $2.69 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $1.78 is for.
Which stocks are comparable to Sensus Healthcare Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sensus Healthcare Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $3.03, calculated fair value $1.78 (−41%), Quality Score 50/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SRTS calculated?
We run Sensus Healthcare Inc through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.78, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Sensus Healthcare Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sensus Healthcare Inc (SRTS)?
The closing price on Sep 23, 2026 was $3.03. Our model-based fair value is $1.78, about −41% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sensus Healthcare Inc right now?
The price sits above even our optimistic bull case ($2.06). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Sensus Healthcare Inc

How large is the market capitalisation of Sensus Healthcare Inc (SRTS)?
The market capitalisation of Sensus Healthcare Inc is $49.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sensus Healthcare Inc (SRTS)?
The price-to-sales ratio of Sensus Healthcare Inc is 1.99 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sensus Healthcare Inc (SRTS)?
Earnings per share at Sensus Healthcare Inc are $−0.4700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sensus Healthcare Inc (SRTS)?
The net margin of Sensus Healthcare Inc is −28.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sensus Healthcare Inc (SRTS)?
The return on equity (ROE) of Sensus Healthcare Inc is −15.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sensus Healthcare Inc (SRTS)?
On an EBIT basis the return on assets of Sensus Healthcare Inc is 6.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sensus Healthcare Inc (SRTS)?
The operating margin of Sensus Healthcare Inc is −128% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sensus Healthcare Inc (SRTS)?
Revenue at Sensus Healthcare Inc is growing −59.3% versus a year earlier (3y avg −14.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sensus Healthcare Inc (SRTS)?
Earnings per share at Sensus Healthcare Inc are growing +433% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Sensus Healthcare Inc (SRTS) hold?
Sensus Healthcare Inc holds more cash than debt, $21.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sensus Healthcare Inc in the live analysis

One click puts Sensus Healthcare Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.